Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate

PLoS Biology

Volumn 11, Issue 11, 2013, Pages

  Caulfield, Timothy ^a   Evans, Jim ^b   McGuire, Amy ^c   McCabe, Christopher ^a   Bubela, Tania ^a   Cook Deegan, Robert ^d   Fishman, Jennifer ^e   Hogarth, Stuart ^f   Miller, Fiona A ^g   Ravitsky, Vardit ^h   Biesecker, Barbara ⁱ   Borry, Pascal ^j   Cho, Mildred K ^k   Carroll, June C ^l   Etchegary, Holly ^m   Joly, Yann ^e   Kato, Kazuto ^n,o   Lee, Sandra Soo Jin ^k,p   Rothenberg, Karen ^q   Sankar, Pamela ^r   Szego, Michael J ^s,t   Ossorio, Pilar ^u,v   Pullman, Daryl ^m   Rousseau, Francois ^w,x   Ungar, Wendy J ^g,y   Wilson, Brenda ^z   more..

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d DUKE UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Granovsky Gluskin Family Medicine Centre   (Canada)

^m MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

ⁿ OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o KYOTO UNIVERSITY   (Japan)

^p STANFORD UNIVERSITY   (United States)

^q NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s University of Toronto McLaughlin Centre and Joint Centre for Bioethics   (Canada)

^t HOSPITAL FOR SICK CHILDREN   (Canada)

^u UNIVERSITY OF WISCONSIN LAW SCHOOL   (United States)

^v MORGRIDGE INSTITUTE FOR RESEARCH   (United States)

^w LAVAL UNIVERSITY   (Canada)

^x UNIVERSITÉ LAVAL   (Canada)

^y HOSPITAL FOR SICK CHILDREN   (Canada)

^z UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENETIC PROCEDURES; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MEDICAL CARE; MICROARRAY ANALYSIS; PATENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; WHOLE GENOME SEQUENCING;

GENOME, HUMAN; GENOMICS; HEALTH POLICY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PUBLIC OPINION; SEQUENCE ANALYSIS, DNA; UNITED STATES;

EID: 84889067060     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001699     Document Type: Article

References (60)

1. Pasche B, Absher D, (2011) Whole-genome sequencing: a step closer to personalized medicine. JAMA 305: 1596-1597.
2. Milner LC, Garrison NA, Magnus D, Cho M (2013) Genomics in the clinic: assessing the landscape of next-generation sequencing in diagnostic laboratories. In: American College of Medical Genetics Annual Meeting. Available: http://ww2.aievolution.com/acm1301/index.cfm?do=abs.viewAbs&abs=1663.
3. Hartocollis A, (2013 April 21) Cancer centers racing to map patients' genes. The New York Times Available: http://www.nytimes.com/2013/04/22/health/patients-genes-seen-as-future-of-cancer-care.html.
4. Leese S, (2013 April 30) US institutions in genomic 'arms race'. PHG Foundation Available: http://www.phgfoundation.org/news/13889/.
5. Kilpivaara O, Aaltonen LA, (2013) Diagnostic cancer genome sequencing and the contribution of germline variants. Science 339: 1559-1562.
6. Yu Y, Wu BL, Wu J, Shen Y, (2012) Exome and whole-genome sequencing as clinical tests: a transformative practice in molecular diagnostics. Clin Chem 58: 1507-1509.
7. Markoff J, (2012 March 7) Cost of gene sequencing falls, raising hopes for medical advances. The New York Times Available: http://www.nytimes.com/2012/03/08/technology/cost-of-gene-sequencing-falls-raising-hopes-for-medical-advances.html.
8. Lin JS, Thompson M, Goddard KAB, Piper MA, Heneghan C, et al. (2012) Evaluating genomic tests from bench to bedside: a practical framework. BMC Med Inform Decis Mak 12: 117.
9. Marshall E, (2012 May 21) Prostate cancer test gets a failing grade. Science Insider Available: http://news.sciencemag.org/2012/05/prostate-cancer-test-gets-failing-grade.
10. Ioannidis JPA, (2013) Biomarker failures. Clin Chem 59: 202-204.
11. Kolata G, (2012 July 7) In treatment for leukemia, glimpses of the future. The New York Times Available: http://www.nytimes.com/2012/07/08/health/in-gene-sequencing-treatment-for-leukemia-glimpses-of-the-future.html.m.
12. Dolan KA, (2013 June 5) Marc Benioff, Mark Zuckerberg and healthcare movers gather at UC San Francisco summit. Forbes Available: http://www.forbes.com/sites/kerryadolan/2013/05/06/marc-benioff-mark-zuckerberg-and-healthcare-movers-gather-at-uc-san-francisco-summit/.
13. Hayden EC, (2011 June 15) Genome study solves twins' mystery condition. Nature doi:10.1038/news.2011.368. Available: http://www.nature.com/news/2011/110615/full/news.2011.368.html.
14. Asadi NB, (2013 January 27) The personalized medicine revolution is almost here. Venture Beat Available: http://venturebeat.com/2013/01/27/the-personalized-medicine-revolution-is-almost-here/.
15. Kimmelman J (2009) Gene transfer and the ethics of first-in-human experiments: lost in translation. New York: Cambridge University Press. 218 p.
16. Hedgecoe A (2004) The politics of personalized medicine: pharmacogenetics in the clinic. New York: Cambridge University Press. 208 p.
17. Hall WD, Mathews R, Morley KI, (2010) Being more realistic about the public health impact of genomic medicine. PLoS Med 7doi:10.1371/journal.pmed.1000347.
18. Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF, (2013) Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 24: 1238-1244.
19. Stenne R, Hurlimann T, Godard B, (2012) Are research papers reporting results from nutrigenetics clinical research a potential source of biohype? Account Res 19: 285-307.
20. Kimmelman J, (2012 December 19) In search of genomic incentives. The Globe and Mail Available: http://www.theglobeandmail.com/news/national/time-to-lead/in-search-of-genomic-incentives/article6534106/.
21. Rinaldi A, (2012) To hype, or not to(o) hype. EMBO reports 13: 303-307.
22. Young NS, Ioannidis JPA, Al-Ubaydli O, (2008) Why current publication practices may distort science. PLoS Med 5: e201 doi:10.1371/journal.pmed.0050201.
23. Yavchitz A, Boutron I, Bafeta A, Marroun I, Charles P, et al. (2012) Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Med 9: e1001308 doi:10.1371/journal.pmed.1001308.
24. Fujimura JH, (1988) The molecular biological bandwagon in cancer research: where social worlds meet. Soc Probl 35: 261-283.
25. Caulfield T, Condit C, (2012) Science and the sources of hype. Public Health Genomics 15: 209-217.
26. Office of New York State Governor Andrew M. Cuomo (2013 January 30) Governor Cuomo announces continued growth at Roswell Park Cancer Institute with regional economic development council funding. Roswell Park Cancer Institute Available: http://www.roswellpark.org/media/news/governor-cuomo-announces-continued-growth-roswell-park-cancer-institute-regional-econom-1.
27. Wetterstrand KA, (2013) DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). National Human Genome Research Institute Available: https://www.genome.gov/sequencingcosts/.
28. Davies K, (2010 October 1) The $1,000,000 genome interpretation. Bio-IT World Available: http://www.bio-itworld.com/2010/10/01/interpretation.html.
29. Miller FA, Hurley J, Morgan S, Goeree R, Collins P, et al. (2002) Predictive genetic tests and health care costs: a policy framework and illustrative estimates. McMaster University Centre for Health Economics and Policy Analysis research working paper 02-03. Hamilton (Ontario): McMaster University Centre for Health Economics and Policy Analysis.
30. Fang J, (2013 February 28) Soon, everybody will be sequenced. SmartPlanet Available: http://www.smartplanet.com/blog/bulletin/soon-everybody-will-be-sequenced/13856.
31. Strickland E, (2013 March 8) Should healthy people get their genomes sequenced? Discover Magazine Available: http://blogs.discovermagazine.com/crux/2013/03/08/should-healthy-people-get-their-genomes-sequenced.
32. Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, et al. (2011) Whole-genome sequencing for optimized patient management. Sci Transl Med 3: 87re3.
33. Mardis ER, Wilson RK, (2009) Cancer genome sequencing: a review. Hum Mol Genet 18: R163-R168.
34. Evans JP, Meslin EM, Marteau TM, Caulfield T, (2011) Deflating the genomic bubble. Science 331: 861-862.
35. Knottnerus JA, editor (2002) The evidence base of clinical diagnosis. London: BMJ Books. 226 p.
36. Lee SSJ, (2013) American DNA: the politics of potentiality in a genomic age. Curr Anthropol 54: S77-S86.
37. Juengst ET, Settersten RA, Fishman JR, McGowan ML, (2012) After the revolution? Ethical and social challenges in "personalized genomic medicine". Per Med 9: 129-139.
38. Prainsack B, Reardon J, Hindmarsh R, Gottweis H, Naue U, et al. (2008) Personal genomes: Misdirected precaution. Nature 456: 34-35.
39. Juengst ET, Flatt MA, Settersten RA, (2012) Personalized genomic medicine and the rhetoric of empowerment. Hastings Center Report 42: 34-40.
40. Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, et al. (2010) Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev pp. CD007275.
41. Collins RE, Wright AJ, Marteau TM, (2011) Impact of communicating personalized genetic risk information on perceived control over the risk: a systematic review. Genet Med 13: 273-277.
42. Bloss CS, Schork NJ, Topol EJ, (2011) Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 364: 524-534.
43. Caulfield T, Chandrasekharan S, Joly Y, Cook-Deegan R, (2013) Harm, hype and evidence: ELSI research and policy guidance. Genome Med 5: 21.
44. Marteau TM, Hollands GJ, Fletcher PC, (2012) Changing human behavior to prevent disease: the importance of targeting automatic processes. Science 337: 1492-1495.
45. Wright CF, Gregory-Jones S, (2010) Size of the direct-to-consumer genomic testing market. Genet Med 12: 594.
46. Evans JP, Berg JS, (2012 December 1) The value of your genome. The Scientist Available: http://www.the-scientist.com/?articles.view/articleNo/33365/title/The-Value-of-Your-Genome/.
47. Evans JP, Berg JS, Olshan AF, Magnuson T, Rimer BK, (2013) We screen newborns, don't we?: Realizing the promise of public health genomics. Genet Med 15: 332-334.
48. Collins FS (2010) The language of life: DNA and the revolution in personalized medicine. New York: HarperCollins Publishers. 368 p.
49. Hagenkord J, (2012 May 17) Empowering patients in the age of genomic medicine. Complete genomics Available: http://www.completegenomics.com/blog/Empowering-Patients-in-the-Age-of-Genomic-Medicine-151880905.html.
50. Duke Center for Personalized Medicine About Us. Duke Personalized Medicine Available: http://www.dukepersonalizedmedicine.org/about_us/.
51. Personalized Medicine Coalition (2009) About the Personalized Medicine Coalition (PMC). Personalized Medicine Coalition Available: http://www.personalizedmedicinecoalition.org/about.
52. Teng K Message from the Director. Cleveland Clinic Center for Personalized Genetic Healthcare Available: http://my.clevelandclinic.org/cph/about-us/message-chair.aspx.
53. Holman CM, (2012) Debunking the myth that whole-genome sequencing infringes thousands of gene patents. Nat Biotechnol 30: 240-244.
54. Nicholson Price II W (2012) Unblocked future: Why gene patents won't hinder whole-genome sequencing and personalized medicine. Cardozo Law Rev 33: 1-37.
55. Nuffield Council on Bioethics (2002) The ethics of patenting DNA: a discussion paper. London: Nuffield Council on Bioethics.
56. Report of the Secretary's Advisory Committee on Genetics, Health, and Society (2010) Gene patents and licensing practices and their impact on patient access to genetic tests. Secretary's Advisory Committee on Genetics, Health, and Society Available: http://oba.od.nih.gov/oba/sacghs/reports/sacghs_patents_report_2010.pdf.
57. Kesselheim Aaron S, Cook-Deegan RM, Winickoff DE, Mello MM, (2013) Gene patenting - supreme court finally speaks. New England J Med 369: 869-875.
58. Cook-Deegan R, Conley JM, Evans JP, Vorhaus D, (2012) The next controversy in genetic testing: clinical data as trade secrets? Eur J Hum Genet pp. 1-4.
59. Kolata G, (2013 April 12) DNA project aims to make public a company's data on cancer genes. The New York Times Available: http://www.nytimes.com/2013/04/13/health/dna-project-aims-to-make-companys-data-public.html?pagewanted=all.
60. Reg4All (2013) Registry for All. Available: http://reg4all.org/.